PTACH (NCH-51) is a SAHA-based novel inhibitor of human HDAC. PTACH exerts potent growth inhibition against various human cancer cells, with EC50 values ranging from 1 to 10 μM.

Quisinostat (JNJ-26481585) 2HCl is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay, modest potent to HDACs 2, 4, 10, and 11.

R306465, also known as JNJ-16241199, is a novel hydroxamate-based histone deacetylase (HDAC) inhibitor with broad-spectrum antitumour activity against solid and haematological malignancies in preclinical models.

Remodelin is an inhibitor of acetyl-transferase NAT10.

Remodelin is an inhibitor of acetyl-transferase NAT10.

Resminostat(RAS2410; 4SC-201) is a potent inhibitor of HDAC1/3/6(IC50=43-72 nM); less potent to HDAC8 with IC50 of 877 nM.

RG2833 is a brain-penetrant inhibitor of HDAC with IC50 values of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

RGFP966 is specific inhibitor of HDAC3, with an IC50 of 0.08 μM and no effective inhibition of any other HDAC at concentrations up to 15 μM.

Rocilinostat (ACY-1215) is a selective HDAC6 inhibitor with IC50 of 5 nM; >10-fold more selective for HDAC6 than HDAC1/2/3 (class I HDACs) with slight activity against HDAC8, minimal activity against HDAC4/5/7/9/11, Sirtuin1, and Sirtuin2.

Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively.

SALL4 peptide FFW (RRKFAKFQWI, FFW peptide) is a potent therapeutic SALL4 peptide antagonist of SALL4-NURD (nucleosome remodeling deacetylase) interaction with target affinity of 23 nM.

Scriptaid(Scriptide; GCK-1026) is an inhibitor of HDAC; shows a greater effect on acetylated H4 than H3.

Splitomicin is a derivative of β-naphthol is an inhibitor of Silent Information Regulator 2 (SIR2).

SR-​4370 is an HDAC inhibitor. SR-​4370 exhibited IC50 values of 0.5 μM, 0.1 μM and 0.06 μM towards HDAC1, HDAC2 and HDAC3, resp.

Tasquinimod is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling.

TH34 is a potent HDAC6/8/10 inhibitor, induceing DNA damage-mediated cell death in human high-grade neuroblastoma cell lines.

Tianeptinaline is a class I HDAC-selective, brain penetrant analogue of tianeptine with IC50 of 0.24, 0.12 and 0.155 uM for HDAC1, 2 and 3 respectively, does not inhibit HDAC6.

Tianeptinostat is a class I HDAC inhibitor with IC50 of 28, 33 and 51 nM for HDAC1, 2 and 3, respectively, also inhibits HDAC6 (IC50=1.6 nM) but not HDAC5 (IC50>80 uM).

Tinostamustine is the first representative of the A-DAC principle, a new approach in chemotherapy that uses fusion technology to combine an alkylating agent with a pan-histone deacetylase inhibitor (HDAC) to simultaneously damage DNA and block damage repa

TMP195 is the most potent and selective class IIa HDAC inhibitor.

TMP269 is a novel and selective class IIa histone deacetylase inhibitor with IC50s of 126/80/36/9 nM for HDAC 4/5/7/9, respectively; 20-400 fold selectivity over class1 HDACs.

Trichostatin A (TSA) is a selective and potent HDAC inhibitor with IC50 of ~1.8 nM; HDAC8 is the only known member of the HDAC-family that is not affected by TSA.